Avacta's Enzymatic Trojan Horse: How One Protein Could Reshape Cancer Drug Delivery

Avacta pivots to a platform biotech with FAP-targeted pre|CISION technology, showing promising data against ADCs and resistant cancers, driving shares up 41% YTD.

London-based biotech Avacta is rewriting its investment narrative. The company has pivoted from a single-asset developer into a platform player built around a deceptively simple biological mechanism — and the market is taking notice.

The catalyst? An enzyme called FAP that lurks in up to 90% of all solid tumors. Rather than targeting specific cell receptors, Avacta's pre|CISION technology uses FAP as a molecular trigger, releasing chemotherapy payloads precisely within tumor tissue. This enzymatic approach decouples drug delivery from traditional cell-surface targets, potentially broadening the addressable patient population.

Clinical Data That Turned Heads

At the company's Science Day in London, management unveiled head-to-head comparisons that put Avacta squarely in competition with oncology's heavy hitters. The second-generation candidate AVA6103 was benchmarked directly against blockbuster antibody-drug conjugates (ADCs) including Enhertu and Datroway. Early data suggest the pre|CISION mechanism deposits toxic cargo more selectively within tumors than these established therapies.

Even more striking were results from the dual-agent program AVA6207. In gastric cancer models, the compound demonstrated sustained therapeutic responses even against tumors that had developed resistance to conventional ADCs. This dual-payload approach, now in third-generation development, aims to overcome the resistance mechanisms that plague difficult-to-treat cancers.

Market Momentum Builds

The stock has been on a tear. Shares surged 14% to 81 GBX on the day of the presentation, hitting a fresh 52-week high. That followed an initial 7% dip — a classic case of traders digesting complex data before the buy-side conviction set in. The rebound continued, with the stock climbing another 8.5% to 77 GBX on Thursday alone.

Year-to-date, Avacta has gained nearly 41%, reflecting growing confidence in the platform's potential. The company's first clinical candidate is already in the Phase 1 FOCUS-01 study, and initial readouts will serve as a critical validation point for the entire pre|CISION strategy.

Runway Secured

Financially, Avacta has bought itself breathing room. An oversubscribed capital raise has extended the cash runway into the first quarter of 2027. That gives management the luxury of advancing multiple programs without immediately needing a partnership — though the data emerging from FOCUS-01 could change that calculus quickly.

The company is now working on a second-generation formulation, AVA6103, designed to maintain stable drug concentrations within tumors. Parallel efforts on AVA6207 aim to deploy two active agents simultaneously, creating a multi-pronged attack on resistant cancer types.

For a company that was once viewed as a one-trick pony, Avacta has transformed into something far more ambitious. Whether the platform delivers on its promise will depend on the clinical data still to come — but the market is already betting that FAP could be the key that unlocks a new class of cancer therapies.